Renalytix AI PLC Podium Presentation and Publication for Data

TIDMRENX

Renalytix AI PLC

24 March 2020

Renalytix AI plc

("RenalytixAI", the "Company")

Podium Presentation and Publication for Health Economics Data

Presentation titled: Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX(TM), to Modify DKD Progression

Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting

Accompanying abstract accepted for publication in American Journal of Kidney Disease

Renalytix AI plc (LSE : RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that data from a study highlighting the health economic benefits associated with KidneyIntelX(TM) testing in diabetic kidney disease populations (DKD) will be presented at the National Kidney Foundation Spring Clinical Meeting being held in the United States. An abstract summarizing key results will be published in the peer reviewed journal, the American Journal of Kidney Disease.

National Kidney Foundation Spring Clinical Meeting (26 March 2020)

Thomas Goss, PharmD, Senior Vice President, Boston Healthcare Associates, will deliver a presentation titled Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX(TM), to Modify DKD Progression during the Late Breaking Abstract session at the National Kidney Foundation's Spring Clinical Meeting. The presentation will highlight t he significant cost savings associated with the implementation of KidneyIntelX(TM) in large health care system patient populations in the United States. The presentation is based on a comprehensive economic model developed by Boston Healthcare Associates utilizing peer reviewed clinical data to estimate the costs associated with chronic kidney disease progression in the U.S. The presentation session will be held on Thursday, 26 March 2020 at 4:15 PM ET. A summary of the presentation results will be made available on the Company's website.

Thomas Goss, Senior Vice President at Boston Healthcare Associates Inc, commented: "The results suggest substantial cost savings can be achieved using KidneyIntelX(TM) to assess CKD patient populations at risk of rapid kidney function decline and/or kidney failure under a number of different scenarios tested."

An abstract summarizing the results will also be published in the May 2020 issue of the American Journal of Kidney Disease ( www.ajkd.org ) , the official journal of the National Kidney Foundation, which is recognized worldwide as a leading source of information devoted to clinical nephrology practice and clinical research.

NKF's Spring Clinical Meeting gathers more than 3,000 nephrology healthcare professionals from across the United States to learn about the newest developments related to all aspects of nephrology practice. Due to the coronavirus and coronavirus disease (COVID-19) outbreak in the United States the meeting is being held as a live virtual event in 2020. Sessions can be accessed through the conference website.

For further information, please contact:

 
Renalytix AI plc                                                      www.renalytixai.com 
James McCullough, CEO                                                     Via Walbrook PR 
 
Stifel (Nominated Adviser & Joint Broker)                              Tel: [phone] 
Alex Price / Jonathan Senior / Ben Maddison 
 
N+1 Singer (Joint Broker)                                              Tel: [phone] 
Aubrey Powell / George Tzimas (Corporate Finance) 
Tom Salvesen (Corporate Broking) 
 
Walbrook PR Limited                        Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne                            Mob: [phone] 
                                                                                      303 
 
 

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of clinical grade, artificial intelligence-enabled in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, and patient stratification for drug clinical trials. For more information, visit renalytixai.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAJJMMTMTATTRM

(END) Dow Jones Newswires

March 24, 2020 03:00 ET (07:00 GMT)